Precision Medicine Approaches When Prostate Cancer Akts Up

Tian Zhang; Daniel J George; Andrew J Armstrong

doi:10.1158/1078-0432.CCR-18-2491

Precision Medicine Approaches When Prostate Cancer Akts Up

Clin Cancer Res. 2019 Feb 1;25(3):901-903. doi: 10.1158/1078-0432.CCR-18-2491. Epub 2018 Sep 11.

Authors

Tian Zhang^{1

2}, Daniel J George^{1

2

3}, Andrew J Armstrong^{4

5}

Affiliations

¹ Division of Medical Oncology, Department of Medicine, Duke University, Durham, North Carolina.
² Duke Cancer Institute and the Duke Prostate and Urologic Cancer Center, Durham, North Carolina.
³ Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery, Duke University, Durham, North Carolina.
⁴ Duke Cancer Institute and the Duke Prostate and Urologic Cancer Center, Durham, North Carolina. andrew.armstrong@duke.edu.
⁵ Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery, Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.

PMID: 30206162
DOI: 10.1158/1078-0432.CCR-18-2491

Abstract

Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activation between the Akt and androgen receptor (AR) pathways. These data revive the rationale for targeting PTEN loss in prostate cancer.See related article by de Bono et al., p. 928.

Publication types

Comment

MeSH terms

Androstenes
Humans
Male
PTEN Phosphohydrolase
Precision Medicine
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant*
Proto-Oncogene Proteins c-akt
Receptors, Androgen

Substances

Androstenes
Receptors, Androgen
Proto-Oncogene Proteins c-akt
PTEN Phosphohydrolase
PTEN protein, human
Prostate-Specific Antigen
abiraterone